AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) already has accelerated approval as a second-line treatment for HER2-mutated NSCLC and is dosed ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

Malaysia's IHH Healthcare said on Thursday its unit is seeking compensation of up to 109.3 billion rupees ($1.25 billion) from Japan's Daiichi Sankyo for its stake buy in India's Fortis Healthcare.

New Delhi, Feb 6 (PTI) Malaysia's IHH Healthcare Berhad on Thursday said its Singaporean arm Northern TK Venture Pte Ltd has increased the claim for damage from Japan's Daiichi Sankyo to up to JPY 199 ...

The company’s PATHWAY HER2 antibody test—used to help screen patients for treatment with Enhertu (trastuzumab deruxtecan-nxki), the antibody-drug conjugate jointly developed by Daiichi Sankyo ...

Approval of Enhertu was granted to AstraZeneca and Daiichi Sankyo. More Information ...

who may be eligible for treatment with Enhertu (trastuzumab deruxtecan; AstraZeneca and Daiichi Sankyo). 1 Last week, the FDA approved Enhertu as the first HER2-directed therapy for adults with ...

MONDAY, Feb. 3, 2025 (HealthDay News) — The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic hormone ...